Collegium Pharmaceutical, Inc. $COLL Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. lowered its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 10.7% during the third quarter, HoldingsChannel reports. The firm owned 1,309,771 shares of the specialty pharmaceutical company’s stock after selling 157,104 shares during the quarter. Principal Financial Group Inc.’s holdings in Collegium Pharmaceutical were worth $45,829,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Federated Hermes Inc. grew its position in Collegium Pharmaceutical by 67.0% in the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 350 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Collegium Pharmaceutical by 1.4% in the 2nd quarter. Franklin Resources Inc. now owns 29,172 shares of the specialty pharmaceutical company’s stock worth $863,000 after acquiring an additional 409 shares during the period. Legal & General Group Plc increased its stake in shares of Collegium Pharmaceutical by 0.6% during the second quarter. Legal & General Group Plc now owns 89,829 shares of the specialty pharmaceutical company’s stock worth $2,656,000 after acquiring an additional 531 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in shares of Collegium Pharmaceutical by 6.9% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,252 shares of the specialty pharmaceutical company’s stock worth $244,000 after acquiring an additional 534 shares during the period. Finally, Sei Investments Co. raised its holdings in Collegium Pharmaceutical by 5.5% during the second quarter. Sei Investments Co. now owns 11,436 shares of the specialty pharmaceutical company’s stock worth $338,000 after purchasing an additional 600 shares in the last quarter.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 17,600 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $48.17, for a total transaction of $847,792.00. Following the completion of the transaction, the executive vice president directly owned 103,613 shares in the company, valued at approximately $4,991,038.21. This trade represents a 14.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Rita J. Balice-Gordon sold 3,650 shares of Collegium Pharmaceutical stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $47.03, for a total transaction of $171,659.50. Following the transaction, the director owned 52,629 shares of the company’s stock, valued at approximately $2,475,141.87. The trade was a 6.49% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.51% of the stock is currently owned by corporate insiders.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock opened at $48.18 on Thursday. The stock has a fifty day moving average price of $47.37 and a 200 day moving average price of $40.48. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.27 and a current ratio of 1.36. The stock has a market cap of $1.52 billion, a PE ratio of 29.93 and a beta of 0.64. Collegium Pharmaceutical, Inc. has a 1 year low of $23.23 and a 1 year high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Thursday, November 6th. The specialty pharmaceutical company reported $2.25 earnings per share for the quarter, beating analysts’ consensus estimates of $1.89 by $0.36. The business had revenue of $209.36 million during the quarter, compared to analysts’ expectations of $191.25 million. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The business’s revenue for the quarter was down 18.9% on a year-over-year basis. During the same quarter last year, the business posted $1.61 earnings per share. Sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

COLL has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Collegium Pharmaceutical in a report on Monday, December 29th. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Needham & Company LLC boosted their target price on shares of Collegium Pharmaceutical from $48.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Finally, Truist Financial set a $55.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday, January 7th. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $52.80.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.